Oligosecretary Myeloma: Prevalence and Its Clinical Significance
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Other: oligosecretary
- Registration Number
- NCT02095379
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
In this study, the investigators aim to investigate the prevalence and clinical course of oligosecretary myeloma.
- Detailed Description
Oligosecretary myeloma is a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day). Patients with oligosecretary myeloma do not have established methods for disease monitoring and clinical informations regarding oligosecretary myeloma are still largely unknown.
In this study, we aimed to investigate the prevalence and clinical course of oligosecretary myeloma.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 390
Inclusion Criteria
- a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
- available clinical data
Read More
Exclusion Criteria
- patients without available clinical data
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description oligosecretary oligosecretary Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
- Primary Outcome Measures
Name Time Method Number of patients with oligosecretary myeloma among multiple myeloma patients up to 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of